Get the Stockscreener App
21.80
1.54%
0.33
Enliven Therapeutics Inc stock is traded at $21.80, with a volume of 167.89K.
It is up +1.54% in the last 24 hours and down -0.91% over the past month.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
See More
Previous Close:
$21.47
Open:
$21.94
24h Volume:
167.89K
Relative Volume:
0.79
Market Cap:
$1.07B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-11.53
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
+0.55%
1M Performance:
-0.91%
6M Performance:
-7.90%
1Y Performance:
+34.90%
1-Day Range:
$21.75
$22.50
1-Week Range:
$21.16
$22.50
52-Week Range:
$10.90
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.80 | 1.07B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
Enliven Therapeutics Inc Stock (ELVN) Latest News
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap DownHere's Why - MarketBeat
(ELVN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock - MSN
Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics COO Anish Patel sells $146,205 in stock By Investing.com - Investing.com South Africa
Trend Tracker for (ELVN) - Stock Traders Daily
Enliven Therapeutics: Promising Innovations in Tyrosine Kinase Inhibitors and Strategic Growth Plans Justify Buy Rating - TipRanks
SG Americas Securities LLC Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001’s High Selectivity and Promising Clinical Data - TipRanks
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares - MarketBeat
Enliven Therapeutics CFO sells $70,177 in stock - MSN
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Objective long/short (ELVN) Report - Stock Traders Daily
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 11.3%Here's Why - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Barclays PLC Acquires 42,012 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $524,706.00 in Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $685,868 in stock By Investing.com - Investing.com Nigeria
Anish Patel, COO of Enliven Therapeutics, sells $685,868 in stock - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 9.8%Time to Sell? - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares - MarketBeat
Enliven's Early Data Stands Out From Peers (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
(ELVN) Trading Advice - Stock Traders Daily
Jane Street Group LLC Sells 22,212 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Jane Street Group LLC Cuts Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.6%Here's What Happened - MarketBeat
Enliven Therapeutics Inc (NASDAQ: ELVN) Stock Forecast: Bearish Sentiment Points To -75.56% Downside In 2025 - Stocks Register
Enliven Therapeutics CFO sells shares worth $94,474 - Investing.com India
Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,350 Shares of Stock - MarketBeat
Franklin Resources Inc. Invests $559,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Barclays PLC Has $1.44 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Barclays PLC Has $1.44 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Geode Capital Management LLC Boosts Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Geode Capital Management LLC Purchases 67,813 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):